Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 329

1.

Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus.

Caballero A, Gregori J, Homs M, Tabernero D, Gonzalez C, Quer J, Blasi M, Casillas R, Nieto L, Riveiro-Barciela M, Esteban R, Buti M, Rodriguez-Frias F.

PLoS One. 2015 Dec 29;10(12):e0144816. doi: 10.1371/journal.pone.0144816. eCollection 2015.

2.

PAGE-B: A risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapy.

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P.

J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795-3. doi: 10.1016/j.jhep.2015.11.035. [Epub ahead of print]

PMID:
26678008
3.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ.

PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.

4.

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.

Ray Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Aguilar Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P.

J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770-9. doi: 10.1016/j.jhep.2015.11.012. [Epub ahead of print]

PMID:
26626497
5.

HaploSNP affinities and linkage map positions illuminate subgenome composition in the octoploid, cultivated strawberry (Fragaria×ananassa).

Sargent DJ, Yang Y, Šurbanovski N, Bianco L, Buti M, Velasco R, Giongo L, Davis TM.

Plant Sci. 2016 Jan;242:140-50. doi: 10.1016/j.plantsci.2015.07.004. Epub 2015 Jul 10.

PMID:
26566832
6.

Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.

Younossi Z, Brown A, Buti M, Fagiuoli S, Mauss S, Rosenberg W, Serfaty L, Srivastava A, Smith N, Stepanova M, Beckerman R.

J Viral Hepat. 2016 Mar;23(3):217-26. doi: 10.1111/jvh.12483. Epub 2015 Oct 20.

PMID:
26482680
7.

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team.

J Hepatol. 2016 Feb;64(2):292-300. doi: 10.1016/j.jhep.2015.09.024. Epub 2015 Oct 8.

PMID:
26453968
8.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators.

Gastroenterology. 2016 Jan;150(1):134-144.e10. doi: 10.1053/j.gastro.2015.09.043. Epub 2015 Oct 8.

9.

Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?

Esteban R, Buti M.

Gastroenterology. 2015 Nov;149(6):1326-30. doi: 10.1053/j.gastro.2015.09.032. Epub 2015 Sep 28. No abstract available.

PMID:
26416329
10.

Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.

de Kanter CT, Buti M, DeMasi R, Ouwerkerk-Mahadevan S, Dofferhoff AS, Witek J, Drenth JP, Zeuzem S, Burger DM.

Antivir Ther. 2015 Sep 17. doi: 10.3851/IMP2994. [Epub ahead of print]

PMID:
26378941
11.

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X.

Clin Infect Dis. 2016 Jan 1;62(1):32-6. doi: 10.1093/cid/civ722. Epub 2015 Sep 14.

PMID:
26371152
12.

Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4).

Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M; COMMAND-4 study team.

Antivir Ther. 2015 Aug 27. doi: 10.3851/IMP2985. [Epub ahead of print]

PMID:
26313445
13.

Management of direct-acting antiviral agent failures.

Buti M, Riveiro-Barciela M, Esteban R.

J Hepatol. 2015 Dec;63(6):1511-22. doi: 10.1016/j.jhep.2015.08.010. Epub 2015 Aug 20. Review.

PMID:
26299621
14.

Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.

Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P.

Cancer. 2015 Oct 15;121(20):3631-8. doi: 10.1002/cncr.29537. Epub 2015 Jul 15.

PMID:
26177866
15.

Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?

Buti M, Casillas R, Riveiro-Barciela M, Homs M, Tabernero D, Salcedo MT, Rodriguez-Frias F, Esteban R.

J Clin Virol. 2015 Jul;68:61-8. doi: 10.1016/j.jcv.2015.05.002. Epub 2015 May 8.

PMID:
26071338
16.

Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.

Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fernández I, Buti M, Millán R, Romero-Gómez M.

J Clin Virol. 2015 Jul;68:56-60. doi: 10.1016/j.jcv.2015.05.010. Epub 2015 May 14.

PMID:
26071337
17.

Profiles and clinical management of hepatitis C patients in Spain: disHCovery study.

Buti M, Franco A, Carmona I, Sánchez-Ruano JJ, Sansó A, Berenguer M, García-Buey L, Hernández-Guerra M, Morillas RM, Ledesma F, Esteban R; disHCovery Study Group.

Rev Esp Quimioter. 2015 Jun;28(3):145-53.

18.

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.

Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas T, Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, Sánchez JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández I, López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela F, Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, Cuadrado A, Hernández-Guerra M.

Ann Hepatol. 2015 Jul-Aug;14(4):477-86.

19.

[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].

Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL; en representación del grupo de investigadores del estudio LEAD-IN.

Gastroenterol Hepatol. 2015 Nov;38(9):517-24. doi: 10.1016/j.gastrohep.2015.04.002. Epub 2015 May 12. Spanish.

PMID:
25976446
20.

Therapy for hepatitis C genotype 3: moving forward.

Buti M, Llaneras J, Riveiro-Barciela M, Esteban R.

J Viral Hepat. 2015 Sep;22(9):683-90. doi: 10.1111/jvh.12419. Epub 2015 May 13.

PMID:
25967352
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk